002826 易明医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.9976.1902.0656.0356.048
总资产报酬率 ROA (%)3.8884.9541.5814.7904.903
投入资产回报率 ROIC (%)4.7716.0251.9715.7715.571

边际利润分析
销售毛利率 (%)80.88968.51451.18943.90835.909
营业利润率 (%)16.2819.4343.5246.5056.704
息税前利润/营业总收入 (%)15.7139.0833.3136.4356.741
净利润/营业总收入 (%)12.1177.2802.3585.3835.993

收益指标分析
经营活动净收益/利润总额(%)70.55148.68582.08860.71042.465
价值变动净收益/利润总额(%)2.4285.8209.8002.6121.813
营业外收支净额/利润总额(%)-3.136-1.8640.4011.7162.752

偿债能力分析
流动比率 (X)2.6883.0132.8622.1953.646
速动比率 (X)2.4742.7782.5182.0213.307
资产负债率 (%)23.32319.52519.15226.34112.658
带息债务/全部投入资本 (%)4.9532.6401.0426.2170.789
股东权益/带息债务 (%)1,905.5263,659.0959,411.0951,495.80312,480.998
股东权益/负债合计 (%)325.887408.531419.293277.879687.402
利息保障倍数 (X)-214.542-50.797-14.698-35.132-44.162

营运能力分析
应收账款周转天数 (天)24.38218.95951.74741.85923.451
存货周转天数 (天)136.05787.71457.78529.65121.024